LTBR and cancer: Collectively, our study develops an immune checkpoint discovery pipeline iMOS and identifies LTBR as a novel immune checkpoint of TAMs that promotes CD8+ T cell exhaustion and G‐MDSC recruitment through noncanonical NF‐κB signaling and Wnt/β‐catenin signaling and proposes a new cancer immunotherapy strategy by targeting LTBR on TAMs.